Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice
2014
Cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) are well validated in clinical research but less in clinical practice. Using a questionnaire, we evaluated the reasons for prescriptions and clinician's expectations concerning CSF biomarkers. The results show that CSF AD biomarkers are mainly required in case of atypical dementia and diagnosis uncertainty that are different from indications in clinical research. In the future, clinicians wish to get new biomarkers that could improve differential diagnosis and could have a good pronostic value. Further studies in routine practice are necessary to precise the role of these biomarkers in the management of patients. 15 16 17 18 19 20
Keywords:
-
Correction
-
Source
-
Cite
-
Save
-
Machine Reading By IdeaReader
18
References
21
Citations
NaN
KQI